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Abstract 
Background: Despite combined modality treatment involving surgery and radiotherapy, a relevant proportion of 
skull‑base chordoma and chondrosarcoma patients develop a local recurrence (LR). This study aims to analyze pat‑
terns of recurrence and correlate LR with a detailed dosimetric analysis.
Methods: 222 patients were treated with proton radiotherapy for chordoma (n = 151) and chondrosarcoma (n = 71) 
at the PSI between 1998 and 2012. All patients underwent surgery, followed by pencil‑beam scanning proton therapy 
to a mean dose of 72.5 ± 2.2GyRBE. A retrospective patterns of recurrence analysis was performed: LR were contoured 
on follow‑up MRI, registered with planning‑imaging and the overlap with initial target structures (GTV,  PTVhigh‑dose, 
 PTVlow‑dose) was calculated. DVH parameters of planning structures and recurrences were calculated and correlated 
with LR using univariate and multivariate cox regression.
Results: After a median follow‑up of 50 months, 35 (16%) LR were observed. Follow‑up MRI imaging was available 
for 27 (77%) of these recurring patients. Only one (3.7%) recurrence was located completely outside the initial PTV 
(surgical pathway recurrence). The mean proportions of LR covered by the initial target structures were 48% (range 
0–86%) for the GTV, 70% (range 0–100%) for  PTVhigh and 83% (range 0–100%) for  PTVlow. In the univariate analy‑
sis, the following DVH parameters were significantly associated with LR: GTV(V < 66GyRBE, p = 0.01), GTV(volume, 
p = 0.02),  PTVhigh(max, p = 0.02),  PTVhigh(V < 66GyRBE, p = 0.03),  PTVhigh(V < 59GyRBE, p = 0.02),  PTVhigh(volume, p = 0.01) 
and GTV(D95, p = 0.05). In the multivariate analysis, only histology (chordoma vs. chondrosarcoma, p = 0.01), 
 PTVhigh(volume, p = 0.05) and GTV(V < 66GyRBE, p = 0.02) were independent prognostic factors for LR.
Conclusion: This study identified DVH parameters, which are associated with the risk of local recurrence after proton 
therapy using pencil‑beam scanning for patients with skull‑base chordoma and chondrosarcoma.
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of recurrence, Dosimetric analysis
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Background
Chordoma and chondrosarcoma of the skull base are rare 
bone tumors [1–4] which are often located in close prox-
imity to critical organs of risk (OAR), including but not 
limited to the brainstem, optic chiasm and optic nerves, 
making complete surgical resection of these tumors chal-
lenging and postoperative high-dose radiotherapy neces-
sary in most cases [5].
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Particle beam radiotherapy offers critical advantages 
compared to photon irradiation in these patients [6, 7], 
not only limited to protons but also carbon ions, as both 
are able to deliver high curative doses even to target vol-
umes in close proximity to OARs, based on their finite 
range in tissue (Bragg-Peak), as well as an overall lower 
integral radiation dose delivered to the patient.
However, despite combined modality treatment involv-
ing surgery and adjuvant radiotherapy, a relevant percent-
age of chordoma and chondrosarcoma patients develop 
a local recurrence [8–10], which is most likely explained 
by the locally aggressive growth pattern. Unfortunately, 
in most cases, we currently lack prognostic parameters 
to assess the risk of local failure of an individual patient. 
Identifying patient, tumor or treatment characteristics, 
associated with an increased risk of local failure, could 
help in the clinical decision-making process.
In a previous study, we identified optic apparatus and/
or brainstem compression, histology and GTV volume 
as prognostic factors for the risk of local failure [11]. The 
present study aims to analyze patterns of recurrence and 
correlate local control with a detailed dosimetric analysis.
Methods
Patient characteristics
This study is based on overall 222 patients, which were 
treated with proton radiotherapy for chordoma (n = 151, 
68%) or low-grade chondrosarcoma (71, 32%) at the Paul 
Scherrer Institute (PSI) between 1998 and 2012. Written 
informed consent was obtained from all patients and the 
study was approved by the local ethics committee (Kan-
tonale Ethikkommission Nordwest- und Zentralschweiz 
(EKNZ, approval number 2020-01071) in accordance 
with ‘good clinical practice’ (GCP) guidelines and the 
Declaration of Helsinki. The patient’s characteristics are 
detailed in Table 1 and have also been described in our 
previous analysis [11].
Patient treatments
All patients underwent surgery with 215 subtotal/near 
complete resections (96.8%) and 7 complete resections 
(3.2%). The gross tumor volume (GTV) was based on 
postoperative planning CT and MRI imaging and had a 
mean volume of 35.7 ± 29.1 cm3. The clinical target vol-
ume (CTV) was based on the preoperative tumor exten-
sion including regions of suspected microscopic spread, 
including the surgical pathway based on institutional 
guidelines. The patients were treated with a larger (GTV 
or CTV expansion of 10  mm in most cases) low-dose 
 PTVlow to a dose of 54  GyRBE and received a sequential 
boost to a smaller (GTV or CTV expansion of 5 mm in 
most cases) high-dose  PTVhigh to a dose of 74  GyRBE or 70 
 GyRBE for chordoma and chondrosarcoma respectively. 
Proton therapy was administered using pencil-beam 
scanning (PBS) technique to a mean dose of 72.5 ± 2.2 
with a prescribed dose of 74  GyRBE for chordoma and 70 
 GyRBE for chondrosarcoma patients at 1.8–2.0  GyRBE per 
fraction. Relative biologic effectiveness (RBE) was defined 
as 1.1 [12]. GTV coverage was maximized with regard to 
OAR dose constraints. Patients were treated exclusively 
with single-field uniform dose (SFUD) until 2003 and 
afterwards with a combination of intensity modulated 
proton therapy (IMPT). The first treatment series was 
typically delivered with three- or four-field SFUD plans, 
including one or two opposed lateral fields with a small 
couch kick and two superior oblique fields. IMPT plans 
were optimized with four non-coplanar fields, two pos-
terior oblique and two anterior oblique fields. Additional 
information regarding irradiation technique, planning 
objectives and OAR dose constraints, has been previ-
ously published [13].
Follow‑up evaluation
Follow-up was performed in intervals of 3–6 months for 
the first 2–3  years and annually thereafter via clinical 
assessment and MRI, as well as CT imaging. Local con-
trol was defined as a reduction in tumor volume or stable 
disease comparing follow-up MRI and CT images with 
imaging prior proton therapy.
Patterns of recurrence and DVH analysis
An in-depth retrospective patterns of recurrence and 
dose volume histogram (DVH) analysis was performed. 
The initial target contour sets were exported from our 
in-house treatment planning system (PSIplan) into the 
treatment planning software Eclipse (Version 13.6, Var-
ian Medical Systems, Palo Alto, USA) and used for both 
the patterns of recurrence and DVH analysis. The local 
recurrences were contoured on the respective follow-up 
MRI imaging studies, registered with the initial planning 
CT and MRI images and the newly generated structures 
(i.e. recurrences) were also exported into Eclipse to cal-
culate the overlap of the local failures with the initial 
target structures GTV,  PTVhigh and  PTVlow (Fig.  1). In 
addition, individual DVH parameters of the initial plan-
ning structures were calculated for all 222 patients. The 
DVH parameters of patients with locally controlled 
tumors were statistically compared to the available DVH 
parameters of the patients who developed a local recur-
rence (n = 32 patients).
Statistical analysis
Local control (LC) was assessed, comparing patients 
with and without recurrence, as well as with and with-
out OAR involvement. Local control was defined as 
stable disease or tumor shrinkage, while radiologically 
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confirmed tumor growth in subsequent images was 
considered a local failure/recurrence. In our previous 
study, we compared the prognostic potential of clini-
cal (histology, patient’s age, gender, compression of the 
brainstem or optic apparatus, tumor volume, recur-
rent status before PT) and technical (number of sur-
geries, weekly fractions) factors for both local control 
and overall survival (OS) [11]. In the present study, 
individual DVH parameters including  Dmin,  Dmax, D98, 
D95,  Dmean, V70, the volume receiving less than 66 
 GyRBE (V < 66GyRBE), and the volume receiving less than 
59  GyRBE (V < 59GyRBE) of initial planning structures 
and recurrences were calculated. These parameters 
were statistically compared between patients with and 
without locally controlled tumors to derive prognostic 
DVH parameters for LC via univariate and multivariate 
cox regression. To account for the outcome differences 
between skull base tumor histology, this was included 
as a categorial variable in the multivariate analysis. 
Concordance index (CI) was calculated for all Cox 
models. Statistical analysis was performed using R soft-
ware. Tests were performed two-sided and differences 
Table 1 Patient characteristics of 222 patients treated with pencil-beam scanning proton therapy
Italics indicate statistically significant differences
Parameter Total N = 222 Chordoma N = 151 ChSa N = 71 p value
Age (years)
Mean (SD) 40.8 (18.4) 43.3 (18.1) 35.6 (18.3) 0.004
Gender
Female (%) 105 (47.3) 65 (43.0) 40 (56.3) 0.09
Male (%) 117 (52.7) 86 (57.0) 31 (43.7)
Recurrent disease
No (%) 171 (77) 115 (76.2) 56 (78.9) 0.76
Yes (%) 51 (23) 36 (23.8) 15 (21.1)
GTV (cc)
Mean (SD) 35.7 (29.1) 35.4 (27.5) 36.1 (32.5) 0.87
Brainstem compression
No (%) 151 (68) 100 (66.2) 51 (71.8) 0.62
Abutment (%) 46 (20.7) 34 (22.5) 12 (16.9)
Yes (%) 25 (11.3) 17 (11.3) 8 (11.3)
Optic apparatus compression
No (%) 154 (69.4) 113 (74.8) 41 (57.7) 0.03
Abutment (%) 44 (19.8) 26 (17.2) 18 (25.4)
Yes (%) 24 (10.8) 12 (7.9) 12 (16.9)
Any compression
No (%) 109 (49.1) 76 (50.3) 33 (46.5) 0.7
Yes (%) 113 (50.9) 75 (49.7) 38 (53.5)
Surgery
Subtotal resection (%) 215 (96.8) 147 (97.3) 68 (95.8) 0.68
Complete resection (%) 7 (3.2) 4 (2.7) 3 (4.2)
Number of surgeries
1 (%) 101 (46.8) 63 (43.4) 38 (53.5) 0.013
2 (%) 78 (36.1) 59 (40.7) 19 (26.8)
3 (%) 23 (12.0) 14 (9.7) 12 (16.9)
4 (%) 6 (2.8) 6 (4.1) 0 (0)
5 (%) 3 (1.4) 3 (2.1) 0 (0)
6 (%) 2 (0.9) 0 (0) 2 (2.8)
Postoperative complications
No (%) 154 (69.4) 106 (70.2) 48 (67.6) 0.89
Yes (%) 68 (30.6) 45 (29.8) 23 (32.4)
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Fig. 1 Proportions of the recurrence covered or not covered by the initial target structures (low‑dose PTV, high‑dose PTV, GTV). Only one 
recurrence was located completely outside the initial PTV (patient 1) and was located within the surgical pathway. The mean proportions of the 
recurrence covered by the initial target structures were 48% (0–86%) for the GTV, 70% (0–100%) for the high‑dose  PTVhigh and 83% (0–100%) for the 
low‑dose  PTVlow. *Surgical pathway recurrence
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with a p value below 0.05 were considered as statisti-
cally significant.
Results
After a median follow-up of 50 months (range 4–176), 35 
(16%) local failures were observed, 5 (7%) in chondrosar-
coma and 30 (20%) in chordoma patients. As described 
in our previous analysis, the 5- and 7-year local con-
trol rates were 81% and 78% (all patients), 76% and 71% 
(chordoma) and 94% (chondrosarcoma), respectively. 
Local control for chondrosarcomas was significantly bet-
ter compared to chordomas (p = 0.04, CI = 0.59). 5- and 
7-year overall survival for the entire cohort were 86% and 
80%, respectively [11].
Follow-up MRI imaging, which was the basis for diag-
nosis of local recurrence, was available for 27 (77%) of 
these 35 recurring patients. The initial PTV including 
DVH could be extracted for 213 (96%) of the total stud-
ied cohort and for 32 (91%) of the recurring patients. In 
some patients, only an initial CTV was available which 
led to a slight decrease in available GTV structures of 
194 (87%) for the total cohort. For the recurring patients, 
there was no difference and the initial GTV was avail-
able for 32 (91%) patients. Thus, the dosimetric evalua-
tion was based on the exported DVH data of 32 patients, 
while the patterns of recurrence analysis was performed 
on 27 patients where follow-up imaging was available. It 
is important to note that neither target delineation prin-
ciples, nor treatment technique or planning objectives 
differed between recurring and non-recurring patients.
The overlap of the local failures with the initial target 
structures GTV, high-dose  PTVhigh and low-dose  PTVlow 
was calculated. Only one recurrence was located com-
pletely outside the initial PTV (Fig. 1, patient 1) and was 
identified as a surgical pathway recurrence. The mean 
proportion of recurrence volumes covered by the initial 
target structures (overlap) were 48% for the initial GTV, 
ranging from 0% (surgical pathway recurrence) to 86% 
(local failure). The initial  PTVhigh covered a mean of 70% 
of the recurrence volumes, ranging from 0 to 100%. The 
larger  PTVlow covered a mean of 83% of recurrence vol-
umes, ranging from 0 to 100% (Fig. 1).
Three examples of in-field recurrences or marginal 
failures, together with the initial GTV (yellow) and 
 PTVhigh (red) structures and dose distribution showing 
 V59GyRBE and  V66GyRBE (in color wash) are shown in 
Fig. 2. The dose of 66  GyRBE corresponds to 95% of the 
prescription dose (D95) in most cases. The first exam-
ple (A) shows a marginal failure in the ethmoid/frontal 
sinus, which may be due to lack of elective coverage in 
this area. In the second example (B), the initial  PTVhigh 
(red) almost completely covers the recurrence (green) 
but because of the brainstem OAR constraint, the dose 
distribution is compromised in this area (right image). 
Example 3 (bottom) shows a marginal failure, likely 
because of chiasm OAR constraints.
The location of the recurrence was analyzed and cat-
egorized into three groups (brainstem, chiasm, other, 
Fig.  3). Recurrences that occurred in the area of the 
brainstem (n = 16, 46%) had a tendency to compress 
or infiltrate the brainstem (n = 8, 23%) or occurred in 
the cerebellopontine angle (n = 4, 11%) or the foramen 
magnum (n = 3, 9%). Sphenoid sinus infiltration was 
rare (n = 1, 3%). Recurrences occurring in the area of 
the chiasm (n = 13, 37%) infiltrated the sphenoid sinus 
(n = 8, 23%) most frequently with only a small percent-
age of brainstem infiltration (n = 2, 6%) or progression 
to the frontotemporal brain tissue (n = 3, 9%). Two of 
the recurred patients (6%) had a recurrence in both the 
area of brainstem and chiasm. There were 6 recurrences 
(17%) outside the brainstem or chiasm areas, 3 (9%) in 
the frontotemporal brain, 2 (6%) in the spinal area and 
one (3%) surgical pathway recurrence in the skull.
In addition to the patterns of recurrence analysis, 
individual DVH parameters of initial planning struc-
tures and recurrences were calculated and correlated 
with local failure (Table  2). In the univariate analy-
sis, we identified several conventional clinical DVH 
parameters, which were significantly associated with 
an increased risk of local recurrence. For the GTV the 
parameters were: GTV (D95, p = 0.05), GTV volume 
receiving less than 66  GyRBE (V < 66GyRBE, p = 0.01), 
GTV volume (p = 0.02). For the  PTVhigh significant 
factors include:  PTVhigh  (Dmax, p = 0.02),  PTVhigh 
volume receiving less than 66  GyRBE (V < 66GyRBE, 
p = 0.03),  PTVhigh volume receiving less than 59  GyRBE 
(V < 59GyRBE, p = 0.02),  PTVhigh volume (p = 0.01).
In the multivariate analysis, histology (chordoma vs 
chondosarcoma, p = 0.009), PTV volume (p = 0.045) 
and GTV (V < 66GyRBE, p = 0.022), (CI = 0.67) remained 
significant and were an independent prognostic factor 
for local tumor control. The GTV volume receiving less 
than  66GyRBE could differentiate between a 5-year local 
control rate of 65% (GTV < 66GyRBE > 3  cc) and 77% 
(GTV < 66GyRBE < 3 cc) for chordoma and between 86% 
(GTV < 66GyRBE > 3 cc) and 97% (GTV < 66GyRBE < 3 cc) 
for chondrosarcoma patients. The PTV volume could 
differentiate between a 5-year local control rate of 
57% (PTV > 120  cc) and 78% (PTV < 120  cc) for chor-
doma and between 73% (PTV > 120  cc) and 97% 
(PTV < 120  cc) for chondrosarcoma patients. Fig-
ure  4 details the Kaplan Meier curves of local control 
in dependence of  PTVhigh volume and GTV volume 
receiving less than  66GyRBE separately for both chor-
doma and chondrosarcoma patients.
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Discussion
Despite combined modality treatment involving sur-
gery and adjuvant radiotherapy, a relevant percentage of 
chordoma and chondrosarcoma patients develop a local 
recurrence [8–10]. A reason might be the close proximity 
or involvement/compression of critical OARs, including 
but not limited to the brainstem, optic chiasm and optic 
nerves, making complete surgical resection and the safe 
delivery of radiation of these tumors challenging. Unfor-
tunately, in most cases, we currently lack prognostic 
parameters to assess the risk of local failure for an indi-
vidual patient.
Fig. 2 Three examples of in‑field recurrences (green) or marginal failures, together with the initial GTV (yellow) and  PTVhigh (red) structures and 
dose distribution showing  V59GyRBE and  V66GyRBE (in color wash). The dose of 66  GyRBE corresponds to the 95% covering isodose (D95) in most 
cases. The first example (a) shows a marginal failure in the ethmoid/frontal sinus due to lack of elective coverage in this area. In the second example 
(b), the initial  PTVhigh (red) nearly completely covers the recurrence (green) but because of the brainstem OAR constraint, the dose distribution is 
compromised in this area (right image). Example 3 (c) shows a marginal failure because of chiasm OAR constraints
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In our previous analysis, we could show that skull-
base tumor patients treated with pencil-beam scan-
ning proton therapy have a favorable outcome with a 
7-year OS and LC of 80% and 78%, respectively [11]. 
These results compare favorably with a recently pub-
lished meta-analysis about intracranial chordoma [14]. 
In addition, we identified optic apparatus and/or brain-
stem compression and histology as prognostic factors 
for the risk of local failure.
Another important finding was that GTV volume could 
be identified as an independent prognostic factor of local 
control, which could be confirmed in the current analy-
sis in addition to PTV volume (Table 2). This provides a 
strong basis for the evaluation of a potential re-resection 
before PT, whenever possible, to reduce the risk of local 
recurrence. In a recently published meta-analysis the 
extent of surgical resection of 670 chordoma patients 
from 15 studies was analyzed [14]. The weighted mean 
percentage of patients receiving gross total resection was 
29%, while subtotal resection was achieved in 61% and 
partial resection in 20% of cases. This suggests that com-
plete resection or re-resection is not always feasible and 
that we might need to include additional parameters with 
prognostic potential to assess the risk of local recurrence 
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Fig. 3 Patterns of recurrence by location. Two of the recurred patients (6%) had a recurrence in both the area of brainstem and chiasm (not shown). 
Recurrences that occurred in the area of the brainstem (n = 16, 46%) had a tendency to compress or infiltrate the brainstem (n = 8, 23%) or occurred 
in the cerebellopontine angle (n = 4, 11%) or the foramen magnum (n = 3, 9%), while sphenoid sinus infiltration was rare (n = 1, 3%). Recurrences 
occurring in the area of the chiasm (n = 13, 37%) were highly likely to infiltrate the sphenoid sinus (n = 8, 23%) with only a small percentage of 
brainstem infiltration (n = 2, 6%) or progression to the frontotemporal brain tissue (n = 3, 9%). There were 6 recurrences (17%) outside the brainstem 
or chiasm areas, 3 (9%) in the frontotemporal brain, 2 (6%) in the spinal area and one (3%) surgical pathway recurrence in the skull
Table 2 Prognostic DVH parameters
Italics indicate statistically significant differences
In the univariate analysis, the following DVH parameters were significantly 
associated with an increased risk of local recurrence: GTV D95 (p = 0.05), 
GTV volume receiving less than 66  GyRBE (V < 66GyRBE, p = 0.01), GTV volume 
(p = 0.02), PTV maximum dose (p = 0.02), PTV volume receiving less than 
66  GyRBE (V < 66GyRBE, p = 0.03), PTV volume receiving less than 59  GyRBE 
(V < 59GyRBE, p = 0.02), PTV volume (p = 0.01). In the multivariate analysis, 
histology (chordoma vs chondosarcoma, p = 0.009), PTV volume (p = 0.045) and 
GTV (V < 66GyRBE, p = 0.022), (CI = 0.67) presented as independent prognostic 
factors of local tumor control
DVH parameters and histology Univariate 
analysis
Multivariate 
analysis
p value CI p value CI
GTV D95 (%) 0.05 0.59 ns ns
GTV V < 66  GyRBE 0.01 0.62 0.022 0.67
GTV Volume 0.02 0.64 ns ns
PTVhigh Max dose  GyRBE 0.02 0.61 ns ns
PTVhigh V < 66  GyRBE 0.03 0.63 ns ns
PTVhigh V < 59  GyRBE 0.02 0.62 ns ns
PTVhigh Volume 0.01 0.63 0.045 0.67
Histology Chordoma versus 
chondrosarcoma
– – 0.009 0.67
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and differentiate between patients with better or worse 
outcomes.
In this study, we could for the first time, identify prog-
nostic DVH parameters for proton therapy delivered to 
chordomas and chondrosarcomas, which are associ-
ated with an increased risk of local recurrence in these 
patients. In our analysis, local control for chondrosar-
comas was significantly better compared to chordomas, 
which is in line with other studies [15]. To account for 
the differences in radiation sensitivity of chordoma and 
chondrosarcoma patients, tumor histology was included 
as a categorial variable in the multivariate analysis and 
could be confirmed as an independent prognostic factor 
for local control. In addition, PTV volume and the GTV 
volume receiving less than  66GyRBE were independent 
prognostic factors. It should be mentioned that many of 
the analyzed parameters are conventional DVH param-
eters, and although they were not independent predictors 
of local failure, multiple GTV and PTV parameters were 
prognostic in the univariate analysis. This suggests that 
it might be feasible to assess the risk of local recurrence 
from these conventional DVH parameters, used in daily 
clinical routine.
Our patterns of recurrence analysis, based on 27 fol-
low-up MRI studies of 35 patients with local recurrence, 
indicates that our delineation paradigm was clinically 
appropriate, with only one case of a surgical pathway 
recurrence (0.5% of total patients), which was not cov-
ered by the initial PTV. This point is highly relevant due 
to the absence of published guidelines for these challeng-
ing tumors. All other recurrences were either completely 
or at least partially covered by the initial target volumes 
(GTV,  PTVhigh,  PTVlow). This suggests that the recur-
rences have developed from the initial tumor, growing 
into and/or infiltrating adjacent organs subsequently. The 
applied dose to the tumor might have been insufficient 
in these cases due to OAR constraints and/or the tumor 
cells might have been particularly radioresistant, which is 
however difficult to assess retrospectively (e.g. biological/
molecular analysis).
In addition, the differing time intervals between the 
proton treatment and available follow-up imaging of 
the recurrences makes it difficult to compare the cover-
age of the recurrences by the initial target volumes. In 
some cases, a longer time interval might have led to an 
increased tumor growth outside the initial PTV or GTV.
So far, no contouring guidelines about chordomas and 
chondrosarcomas of the skull-base have been published, 
thus our analysis might provide a basis for clinical deci-
sion making and risk assessment of an individual skull-
base tumor patient. Regarding target volume delineation, 
it should be noted that the sphenoid sinus should be 
covered in case of chiasm involvement, as patients with 
tumors in this location had a high risk of local recurrence 
in the sphenoid sinus in our analysis.
There are several limitations of this study, including 
the long time interval between the first treated patient 
in 1998 and the last patient of this analysis in 2012. The 
available imaging, imaging quality and to some extent 
treatment planning changed slightly over time and image 
registration of the recurrences can be a challenging pro-
cess. Some patients were treated with single-field uni-
form dose (SFUD) and others with intensity modulated 
proton therapy (IMPT). It also needs to be mentioned 
that local tumor control could also be achieved in a pro-
portion of patients, whose DVH characteristics did not 
fully meet the planning objectives, suggesting that indi-
vidual radiation resistance may be an additional impor-
tant factor. In addition, the retrospective character of our 
analysis is prone to bias. Strengths of our analysis include 
the large patient cohort, inclusion of modern IMPT tech-
niques, as well as the high percentage of available follow-
up imaging for the recurred patients.
In summary, we were able to identify prognostic DVH 
parameters, associated with the risk of local recurrence 
in chordoma and chondrosarcoma patients treated with 
proton therapy. We have shown that the residual tumor 
volume and the coverage of the PTV was of paramount 
importance. These metrics may be used for clinical deci-
sion making when treating these challenging patients, 
although confirmatory results are required.
Fig. 4 Local control in dependence of  PTVhigh volume and GTV volume receiving less than  66GyRBE separately for both chordoma and 
chondrosarcoma patients. Apart from tumor histology (chordoma vs chondosarcoma, p = 0.009), both  PTVhigh volume (p = 0.045) and GTV 
(V < 66GyRBE, p = 0.022) were significant independent prognostic factors of local failure in the multivariate analysis. The PTV volume could 
differentiate between a 5‑year local control rate of 57% (PTV > 120 cc) and 78% (PTV < 120 cc) for chordoma (a) and between 73% (PTV > 120 cc) 
and 97% (PTV < 120 cc) for chondrosarcoma patients (c). The GTV volume receiving less than  66GyRBE could differentiate between a 5‑year local 
control rate of 65% (GTV < 66GyRBE > 3 cc) and 77% (GTV < 66GyRBE < 3 cc) for chordoma (b) and between 86% (GTV < 66GyRBE > 3 cc) and 97% 
(GTV < 66GyRBE < 3 cc) for chondrosarcoma patients (d)
(See figure on next page.)
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